Hypofibrinogenemia is a condition where your blood contains lower-than-normal levels of fibrinogen, a protein essential for forming blood clots. Normal plasma fibrinogen ranges between 200 and 400 mg/dL; hypofibrinogenemia is generally defined as levels below 150 mg/dL. The condition can be inherited or acquired, and its severity ranges from barely noticeable to life-threatening depending on how low fibrinogen drops.
How Fibrinogen Works in Blood Clotting
Fibrinogen is a large protein made by the liver that circulates in your blood at all times. When you get a cut or injury, a chain reaction converts fibrinogen into fibrin, which forms a mesh-like structure that traps blood cells and creates a stable clot. Without enough fibrinogen, this process slows down or fails, leaving you vulnerable to prolonged or excessive bleeding.
Fibrinogen also plays roles beyond clot formation. It helps platelets stick together and participates in wound healing and inflammation. So when levels drop significantly, the effects can ripple across several body systems.
Severity Levels
The European Network of Rare Bleeding Disorders classifies hypofibrinogenemia into three tiers based on functional fibrinogen levels in the blood:
- Mild: fibrinogen between 1.0 g/L (100 mg/dL) and the lower limit of normal
- Moderate: fibrinogen between 0.5 and 0.9 g/L (50 to 90 mg/dL)
- Severe: fibrinogen below 0.5 g/L (50 mg/dL)
Below 0.1 g/L, the condition is reclassified as afibrinogenemia, meaning fibrinogen is essentially absent. The distinction matters because treatment urgency and bleeding risk increase substantially at each tier.
Congenital vs. Acquired Causes
Congenital hypofibrinogenemia results from mutations in the genes that encode fibrinogen’s three component chains: FGA, FGB, and FGG. These mutations reduce the amount of fibrinogen the liver produces or prevent it from being assembled correctly. The condition typically follows an autosomal inheritance pattern, meaning a child who inherits one mutated copy from a parent will often have mildly reduced fibrinogen, while inheriting mutations from both parents leads to more severe deficiency. Research has shown that even within a single family, different mutations across all three fibrinogen genes can combine to lower levels, and microscopic analysis of affected patients’ clots reveals thinner fibrin fibers with a looser, more porous structure that is less effective at stopping bleeding.
Acquired hypofibrinogenemia develops later in life as a result of another medical condition. The most common causes include liver disease (since the liver manufactures fibrinogen), disseminated intravascular coagulation (a dangerous condition where the body uses up clotting factors faster than it can replace them), and certain inflammatory disorders. Some medications, plasma exchange procedures, and rarely, antibodies that attack fibrinogen can also drive levels down. In acquired cases, treating the underlying condition often helps restore fibrinogen levels.
Symptoms and Bleeding Patterns
Many people with mild hypofibrinogenemia have no symptoms at all and only discover the condition through routine blood work or after unexpectedly heavy bleeding during surgery or dental procedures. As levels drop into the moderate and severe range, symptoms become more apparent.
Common bleeding patterns include easy bruising, nosebleeds, heavy or prolonged menstrual periods, and prolonged bleeding from cuts or wounds. More serious manifestations can include bleeding into muscles or joints, gastrointestinal bleeding, and in rare cases, bleeding within the skull. Women with hypofibrinogenemia may first notice the condition through unusually heavy periods or complications during pregnancy. The general trend is straightforward: the lower the fibrinogen, the greater the bleeding risk, though individual variation exists.
How It’s Diagnosed
The standard test for measuring fibrinogen is the Clauss assay. In this test, a sample of your diluted plasma is exposed to a large amount of thrombin (the enzyme that converts fibrinogen to fibrin), and the time it takes for a clot to form is compared against a reference curve. Faster clotting means more fibrinogen; slower clotting means less.
A second method estimates fibrinogen indirectly during a prothrombin time test by measuring changes in the optical density of the sample as a clot forms. This approach is more automated but can sometimes give slightly different readings than the Clauss method, particularly at very low fibrinogen levels. For a definitive diagnosis, especially when congenital hypofibrinogenemia is suspected, both functional and antigen-based testing may be used alongside genetic testing of the FGA, FGB, and FGG genes.
Treatment for Acute Bleeding
When someone with hypofibrinogenemia is actively bleeding or needs surgery, the primary treatment is replacing the missing fibrinogen. Two main products are used for this: purified fibrinogen concentrate and cryoprecipitate (a blood product derived from donated plasma that contains concentrated fibrinogen along with other clotting factors).
Fibrinogen concentrate offers more predictable dosing because each vial contains a standardized amount. Cryoprecipitate varies more from batch to batch in its fibrinogen content and also contains other clotting factors that can, in some cases, raise the risk of blood clots. In a randomized trial of 735 cardiac surgery patients with hypofibrinogenemia, fibrinogen concentrate performed equally well as cryoprecipitate for controlling bleeding. A smaller trial in patients undergoing abdominal surgery found both products achieved full bleeding control, but the cryoprecipitate group experienced seven blood clot complications (pulmonary embolisms and deep vein clots) while the fibrinogen concentrate group had none.
The general target during active bleeding is to raise fibrinogen to at least 100 mg/dL and maintain it there until bleeding stops. For people whose baseline level is known, dosing is calculated based on body weight and the gap between the current and target level.
Long-Term Management
Routine preventive infusions of fibrinogen are not currently recommended for most patients. The risks of regular treatment, including allergic reactions, the theoretical possibility of developing antibodies against fibrinogen, and blood clot complications, generally outweigh the benefits for people with mild or moderate disease. However, after a life-threatening bleed such as intracranial hemorrhage, secondary preventive treatment may be started with the goal of keeping fibrinogen above 0.5 g/L (50 mg/dL).
For specific situations, targeted strategies help. Before dental procedures, antifibrinolytic medications (drugs that prevent clots from breaking down too quickly) can reduce bleeding risk without requiring fibrinogen infusions. Women with heavy menstrual bleeding can often manage symptoms effectively with hormonal birth control, which also helps prevent bleeding from ovulation-related complications. Patients with very low fibrinogen levels are advised to avoid intramuscular injections, which can cause deep tissue bleeding, and should be vaccinated against hepatitis A and B through subcutaneous injection instead.
Pregnancy Risks and Management
Pregnancy poses particular challenges for women with hypofibrinogenemia. Low fibrinogen levels have been linked to miscarriage, placental abruption (where the placenta separates from the uterine wall), fetal growth restriction, and premature delivery. Fibrinogen plays a critical role in maintaining the placental blood supply, so deficiency can compromise the pregnancy even in the absence of visible bleeding.
Based on clinical experience, maintaining fibrinogen trough levels above 1.0 g/L (100 mg/dL) throughout pregnancy helps prevent miscarriage and other complications. During labor and delivery, higher targets of 1.5 to 2.0 g/L (150 to 200 mg/dL) are recommended to reduce the risk of placental abruption and postpartum hemorrhage. Successful pregnancies have been reported in women with hypofibrinogenemia who received regular fibrinogen replacement throughout pregnancy, with close monitoring to keep levels within the target range.